Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced the encore presentation of findings from a post-hoc analysis examining the effects of icosapent ethyl (Vascepa®) on Apolipoprotein C-III (ApoC-III) levels in both very high triglyceride (VHTG) and high triglyceride (HTG) patient populations. The poster titled, “Icosapent Ethyl (eicosapentaenoic acid ethyl ester): Effects on Apolipoprotein C-III in Patients from the MARINE and ANCHOR Studies,” will be on display at the European Society of Cardiology 2015 Annual Congress in London, England, Session 302 Poster Session #2. The results will be presented by lead investigator, Dr. Christie Ballantyne, Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center on Sunday, August 30 at 10:00 AM GMT.

“This analysis extends the findings to date of the potential lipid and lipoprotein modifying benefits Vascepa possesses in patients with elevated triglyceride (TG) levels,” said Dr. Ballantyne. “It also extends our understanding of the effects Vascepa® has on top of statin therapy.”

The analysis evaluated the effects of EPA-only prescription Vascepa, alone or in combination with statin therapy, on ApoC-III levels in 148 patients with VHTG levels in the MARINE study of Vascepa and 612 patients with HTG levels in the ANCHOR study of Vascepa. In MARINE, Vascepa 4 g/day statistically significantly reduced ApoC-III levels by 25.1% (P < 0.0001) versus placebo. In ANCHOR, Vascepa 4 g/day statistically significantly reduced ApoC-III levels by 19.2% (P < 0.0001) versus placebo. The findings, originally presented at the National Lipid Association Annual Scientific Sessions in 2014, show that at both 4g/day and 2g/day compared to placebo, Vascepa, alone or in combination with statin therapy, significantly reduced ApoC-III levels in adult patients in the MARINE and ANCHOR studies, in which Vascepa also significantly lowered TG levels without raising LDL-C.

Further study is needed to determine if the effects of Vascepa, including those on ApoC-III, in patients with hypertriglyceridemia would have clinically meaningful benefit in the human body. (Original Source)

Shares of Oncolytics Biotech closed yesterday at $0.5199. ONCY has a 1-year high of $1.42 and a 1-year low of $0.40. The stock’s 50-day moving average is $0.58 and its 200-day moving average is $0.67.

On the ratings front, Canaccord Genuity analyst Neil Maruoka maintained a Buy rating on ONCY, with a price target of $2.50, in a report issued on June 8. The current price target represents a potential upside of 380.8% from where the stock is currently trading. According to TipRanks.com, Maruoka has a total average return of 0.2%, a 38.5% success rate, and is ranked #2322 out of 3734 analysts.

Oncolytics Biotech Inc is a development stage biopharmaceutical company. It is engaged in the discovery and development of pharmaceutical products for the treatment of cancer.